With upsized opportunity fund closing at €360M, Forbion readies to build on portfolio with three-pronged strategy
Forbion is carving out a strategy that’s differentiated from most biotech opportunity funds
With a final close for its latest fund well exceeding its target, Forbion is preparing to build on its trio of initial investments by carving out a strategy that’s differentiated from most opportunity funds for biotechs with a team of advisers that’s a who’s who of European CEOs.
Forbion plans to deploy the €360 million ($430 million) Forbion Growth Opportunities Fund I via 10-12 investments of up €35 million per deal in private, clinical-stage companies, crossover capital and what it calls “undervalued” public companies. ...